Activation of the GLP-1R augments glucose-stimulated insulin secretion, and GLP-1 mimetics and dipeptidyl peptidase-4 inhibitors (which block degradation of GLP-1) are used in the treatment of type 2 diabetes [70,71]. The gene discussed is INS; the disease is type 2 diabetes mellitus.